Tag: orsiro

Resolute Onyx matches Orsiro at two years in all-comers’ patients

Two-year data from the BIONYX trial show that all-comer patients who underwent percutaneous coro...

Study establishes safety and efficacy of ticagrelor monotherapy in acute coronary syndrome patients treated with Orsiro

According to recently presented TICO trial data, a press release reports, patients with acute co...

CRT 2020: Biotronik reports three-year results for Orsiro DES from BIOFLOW-V trial

Biotronik has announced three-year data from the BIOFLOW-V trial, which were presented at the Ca...

ESC 2019: Ultrathin strut Orsiro better than thin strut Xience for STEMI patients

One-year data from the BIOSTEMI study, simultaneously published in The Lancet and presented at t...

EuroPCR 2019: Ultrathin stent demonstrates benefits in small vessels

Late-breaking trial data presented at EuroPCR 2019 (20–24 May, Paris, France) on three year outc...

CRT 2019: Three-year data shows trend towards lower target vessel failure with Orsiro vs. Resolute Integrity and Synergy

Three-year outcome data from the BIO-RESORT randomised controlled trial, which were presented at...

FDA approves Orsiro for use in the USA

  The US FDA have approved Biotronik’s drug-eluting stent Orsiro. A press release states...

Orsiro may be the new benchmark for comparison in drug-eluting stent trials

At the 2018 Transcatheter Cardiovascular Therapeutics (TCT) meeting (21–25 September, San Diego,...

TCT 2018: Orsiro continues to have lower rates of target lesion failure than Xience

Two-year data from the BIOFLOW-V randomised trial—which compared a sirolimus stent with a biodeg...

TCT 2018: Lower rate of stent thrombosis with Resolute Onyx vs. Orsiro

Data presented yesterday at the 2018 Transcatheter Cardiovascular Therapeutics (TCT) meeting (21...

ESC 2018: Higher all-cause mortality with Orsiro at five years than with Xience

According to the five-year results of the BIOSCIENCE trial, sirolimus-eluting stents with a biod...

EuroPCR 2018: One- to two-year landmark analysis shows significantly lower target lesion failure with Orsiro vs. Resolute Integrity

Two-year outcome data from the BIO-RESORT randomised controlled trial, which were presented in a...

CIT 2018: BIOFLOW-VI confirms non-inferiority of Orsiro to Xience

Nine and 12-month data for Orsiro—presented by Yang Yue Jin (Fu-Wai Hospital, National Center of...

Enrolment complete in BIOSTEMI study

Biotronik has announced that patient enrolment for the BIOSTEMI study has been completed. A pres...

Japanese Ministry of Health approve Biotronik’s Orsiro drug-eluting stent

According to a Biotronik press release, the Japanese Ministry of Health has approved the company...

ESC 2017: Significantly lower event rates with Orsiro than with Xience

  Results from the BIOFLOW V study indicate that patients who undergo percutaneous coron...

BIOFLOW-IV confirms non-inferiority of Biotronik’s Orsiro in Japan

The 12-month results of Biotronik’s BIOFLOW-IV multicentre clinical study have been presented at...

TCT 2016: All comers study finds no differences between Orsiro, Synergy and Resolute Integrity

BIO-RESORT, presented at TCT today during a late-breaking trial session, has found no significant di...

Risk of device thrombosis may be significantly higher with Absorb than with Xience, Promus or Orsiro

A network meta-analysis, published in JACC: Cardiovascular Interventions, indicates that three c...